Calcineurin inhibitor-free monotherapy in human leukocyte antigen-identical live donor renal transplantation

Transplantation

Volumn 91, Issue 3, 2011, Pages 330-333

  Venot, Marion ^a   Abboud, Imad ^a,b   Duboust, Alain ^a,b   Michel, Catherine ^b,c   Suberbielle, Caroline ^a,b   Vérine, Jerome ^a,b   Flamant, Martin ^b,c   Morelon, Emmanuel ^d,e   Glotz, Denis ^a,b   Peraldi, Marie Noelle ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

Calcineurin inhibitor free therapy; Corticosteroid free therapy; HLA identical; Kidney transplantation; Mycophenolate mofetil

Indexed keywords

ATORVASTATIN; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; COTRIMOXAZOLE; CREATININE; HLA ANTIGEN; LIPID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIVING DONOR; LOADING DRUG DOSE; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PYELONEPHRITIS;

ADULT; ANTILYMPHOCYTE SERUM; BIOPSY; CALCINEURIN; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 79951473731     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182033ef0     Document Type: Article

References (26)

1. United Network for Organ Sharing [database on the internet]. Richmond, VA, Organ Procurement and Transplantation Network Data. 2007. Available at: http://unos.org/.
2. Terasaki PI, Cho Y, Takemoto S, et al. Twenty-year follow-up on the effectof HLA matching on kidney transplant survival and prediction of future twenty-year survival. Transplant Proc 1996; 28: 1144.
3. Terasaki PI. The HLA-matching effect in different cohorts of kidney transplant recipients. Clin Transpl 2000: 497.
4. Shimmura H, Tanabe K, Ishida H, et al. Long-term results of living kidney transplantation from HLA-identical sibling donors under cal-cineurin inhibitor immunosuppression. Int J Urol 2006; 13: 502.
5. Sumrani N, Delaney V, Ding Z, et al. HLA-identical renal transplants: Impact of cyclosporine on intermediate-term survival and renal function. Am J Kidney Dis 1990; 16: 417.
6. Schweizer RT, Roper L, Hull D, et al. Low-dose triple immunosuppression for HLA identical sibling kidney transplants. Transplant Proc 1992; 24: 2609. (Pubitemid 23011615)
7. De Mattos AM, Bennett WM, Barry JM, et al. HLA-identical sibling renal transplantation-A 21-yr single-center experience. Clin Transplant 1999; 13: 158.
8. Peddi VR, Weiskittel P, Alexander JW, et al. HLA-identical renal transplant recipients: Immunosuppression, long-term complications, and survival. Transplant Proc 2001; 33: 3411.
9. Keitel E, Santos AF, Alves MA, et al. Immunosuppression protocols for HLA identical renal transplant recipients. Transplant Proc 2003; 35: 1074.
10. Stratta RJ, Armbrust MJ, Oh CS, et al. Withdrawal of steroid immunosup-pression in renal transplant recipients. Transplantation 1988; 45: 323.
11. Woodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant 2005; 5: 2740.
12. MacDonald AS, Belitsky P, Bitter-Suermann H, et al. Cyclosporine as primary therapy for a matched living related donor kidney graft recipients. Transplant Proc 1989; 21: 1667.
13. Moore J, Middleton L, Cockwell P, et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis. Transplantation 2009; 87: 591.
14. Alexander JW, Goodman HR, Cardi M, et al. Simultaneous corticoste-roid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int 2006; 19: 295.
15. Walker JK, Alloway RR, Roy-Chaudhury P, et al. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation. Transplantation 2009; 87: 408.
16. Kirk AD, Mannon RD, Swanson SJ, et al. Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int 2005; 18: 2.
17. Yang H. Maintenance immunosuppression regimens: Conversion, minimization, withdrawal, and avoidance. Am J Kidney Dis 2006; 47: S37.
18. Jaber JJ, Feustel PJ, Elbahloul O, et al. Early steroid withdrawal therapy in renal transplant recipients: A steroid-free sirolimus and cellcept-based calcineurin inhibitor-minimization protocol. Clin Transplant 2007; 21: 101.
19. Govil A, Golconda MS, Olyaei AJ, et al. Calcineurin inhibitor withdrawal inHLA-identical sibling kidney transplant recipients: A 10-year single center experience. Transplantation 2006; 82(1 suppl 2): 285.
20. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
21. The Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
22. Vitko S, Wlodarczyk Z, Kyllonen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J Transplant 2006; 6: 531.
23. Moon JI, Kim YS, Chung SY, et al. Long-term results of kidney transplantation between HLA-identical siblings. Surg Today 2001; 31: 123.
24. Albrechtsen D, Flatmark A, Leivestad T, et al. Efficacy of cyclosporine in renal transplantation from HLA haploidentical living donors: No benefit oftransfusionoradditional azathioprine. Transplant Proc1990; 22: 214.
25. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 11: 2496.
26. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.